基因治疗原发性高血压的新途径:内皮型一氧化氮合成酶CDNA腺病毒载体在人胎肾293细胞的表达

A new approach to gene therapy of primary hypertension:expression of endothelial nitric oxide synthase CNDA adenovirus vector in human fetal kidney 293 cells

研究内皮型一氧化氮合成酶（endothelialnitric oxide synthase,eNOS)CDNA 腺病毒载体 PadRSVeNOSCDNA 导入在人胎肾 293细胞 ( )中的表达。方法:大量制备及纯化质粒 eNOSCDNA ,将纯化eNOSCDNA 载体通过脂质体转染 293细胞48h 后,应用化学比色法测定293细胞提取物NOS 活性。结果:被转染 293细胞 NOS活性显著提高于未转染293细胞 NOS 活性犤( 0.62±0.03),(0.093±0.01)kU /L,P <0.001犦。结论:PA dRSVeNOSCDNA 导入人胎肾 293细胞是一种能使 NOS 活性显著升高的方法,为基因治疗原发性高血压及肾脏血管性疾病研究提供一条新的途径。

AIM:To explore the expression of endothelial nitric oxide synthase (eNOS) CDNA adenovirus vector PadRSVeNOSCDNA transferring into human fetal kidney 293 cells. METHODS:Plenty of eNOSCDNA plasmids were produced and purified. 293 cells were transfected with the purified eNOSCDNA plasmids for 48 hours by liposome coated DNA. The activity of NOS in extraction of 293 cells was measured by chemocolorimetry. RESULTS:NOS activity of PAdRSVeNOSCDNA transfected 293 cells were significantly higher than that of PADRSV4 transfected 293 cells (0.62±0.03 vs 0.093±0.01 KU/L, P< 0.001).